Acid-Suppression Therapy for Gastroesophageal Reflux Disease and the Therapeutic Gap

[1]  J. Pandolfino,et al.  Biomarkers of Reflux Disease. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  O. Khan,et al.  Is the Stretta procedure as effective as the best medical and surgical treatments for gastro-oesophageal reflux disease? A best evidence topic. , 2016, International journal of surgery.

[3]  S. Horgan,et al.  Long-term Outcomes of Patients Receiving a Magnetic Sphincter Augmentation Device for Gastroesophageal Reflux. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  J. Tack,et al.  Management of refractory typical GERD symptoms , 2016, Nature Reviews Gastroenterology &Hepatology.

[5]  C. Reimer,et al.  Randomised clinical trial: alginate (Gaviscon Advance) vs. placebo as add‐on therapy in reflux patients with inadequate response to a once daily proton pump inhibitor , 2016, Alimentary pharmacology & therapeutics.

[6]  P. Kahrilas,et al.  Therapy: Risks associated with chronic PPI use — signal or noise? , 2016, Nature Reviews Gastroenterology &Hepatology.

[7]  P. Kahrilas,et al.  Editorial: Low-Dose Tricyclics for Esophageal Hypersensitivity: Is It All Placebo Effect? , 2016, The American Journal of Gastroenterology.

[8]  N. Pausawasdi,et al.  Imipramine for Treatment of Esophageal Hypersensitivity and Functional Heartburn: A Randomized Placebo-Controlled Trial , 2016, The American Journal of Gastroenterology.

[9]  Zhi-wei Hu,et al.  Comparison of Stretta procedure and toupet fundoplication for gastroesophageal reflux disease-related extra-esophageal symptoms. , 2015, World journal of gastroenterology.

[10]  Hongjoo Kim,et al.  Long-term follow-up results of endoscopic treatment of gastroesophageal reflux disease with the MUSE™ endoscopic stapling device , 2015, Surgical Endoscopy.

[11]  J. Pandolfino,et al.  Majority of symptoms in esophageal reflux PPI non‐responders are not related to reflux , 2015, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[12]  S. Karmali,et al.  Update on novel endoscopic therapies to treat gastroesophageal reflux disease: A review. , 2015, World journal of gastrointestinal endoscopy.

[13]  Yanchao,et al.  Early and Midterm Outcome After Laparoscopic Fundoplication and a Minimally Invasive Endoscopic Procedure in Patients with Gastroesophageal Reflux Disease: A Prospective Observational Study , 2015 .

[14]  J. Richter,et al.  No evidence for efficacy of radiofrequency ablation for treatment of gastroesophageal reflux disease: a systematic review and meta-analysis. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[15]  H. Feußner,et al.  Endoluminal perforation of a magnetic antireflux device , 2015, Surgical Endoscopy.

[16]  A. Bapaye,et al.  Trans-oral anterior fundoplication: 5-year follow-up of pilot study , 2015, Surgical Endoscopy.

[17]  Erik B. Wilson,et al.  Efficacy of transoral fundoplication vs omeprazole for treatment of regurgitation in a randomized controlled trial. , 2015, Gastroenterology.

[18]  G. Boeckxstaens,et al.  Increased proximal reflux in a hypersensitive esophagus might explain symptoms resistant to proton pump inhibitors in patients with gastroesophageal reflux disease. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[19]  S. Horgan,et al.  Endoscopic anterior fundoplication with the Medigus Ultrasonic Surgical Endostapler (MUSE™) for gastroesophageal reflux disease: 6-month results from a multi-center prospective trial , 2014, Surgical Endoscopy.

[20]  C. Zhang,et al.  Five-year follow-up of a prospective study comparing laparoscopic Nissen fundoplication with Stretta radiofrequency for gastroesophageal reflux disease. , 2014, Minerva chirurgica.

[21]  Mohammad R. Ostovaneh,et al.  Comparing omeprazole with fluoxetine for treatment of patients with heartburn and normal endoscopy who failed once daily proton pump inhibitors: Double‐blind placebo‐controlled trial , 2014, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[22]  G. Boeckxstaens,et al.  Symptomatic reflux disease: the present, the past and the future , 2014, Gut.

[23]  R. Farré,et al.  Effect of nortriptyline on brain responses to painful esophageal acid infusion in patients with non‐erosive reflux disease , 2014, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[24]  G. Boeckxstaens,et al.  An alginate-antacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[25]  P. Funch‐jensen,et al.  Randomized clinical trial: inhibition of the TRPV1 system in patients with nonerosive gastroesophageal reflux disease and a partial response to PPI treatment is not associated with analgesia to esophageal experimental pain , 2013, Scandinavian journal of gastroenterology.

[26]  Peter J. Richardson,et al.  Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett's oesophagus: a case-control study , 2013, Gut.

[27]  G. Karamanolis,et al.  Selective Serotonin Reuptake Inhibitors for the Treatment of Hypersensitive Esophagus: A Randomized, Double-Blind, Placebo-Controlled Study , 2012, The American Journal of Gastroenterology.

[28]  Bryan K. Smith,et al.  Weight loss can lead to resolution of gastroesophageal reflux disease symptoms: A prospective intervention trial , 2012, Obesity.

[29]  N. Shaheen,et al.  Efficacy and safety of lesogaberan in gastro-oesophageal reflux disease: a randomised controlled trial , 2012, Gut.

[30]  G. Boeckxstaens,et al.  Failure of reflux inhibitors in clinical trials: bad drugs or wrong patients? , 2012, Gut.

[31]  R. Bisschops,et al.  A Double-Blind Sham-Controlled Study of the Effect of Radiofrequency Energy on Symptoms and Distensibility of the Gastro-Esophageal Junction in GERD , 2012, The American Journal of Gastroenterology.

[32]  R. Fass,et al.  Symptom indexes in refractory gastroesophageal reflux disease: overrated or misunderstood? , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[33]  N. Vakil,et al.  Arbaclofen Placarbil in GERD: A Randomized, Double-Blind, Placebo-Controlled Study , 2011, The American Journal of Gastroenterology.

[34]  P. Svoboda,et al.  Our experience with transoral incisionless plication of gastroesophageal reflux disease: NOTES procedure. , 2011, Hepato-gastroenterology.

[35]  C. Ell,et al.  Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. , 2011, JAMA.

[36]  D. Sifrim,et al.  The refluxate: The impact of its magnitude, composition and distribution. , 2010, Best practice & research. Clinical gastroenterology.

[37]  Jacobson,et al.  (R)-(3-Amino-2-fluoropropyl) Phosphinic Acid (AZD3355), a Novel GABAB Receptor Agonist, Inhibits Transient Lower Esophageal Sphincter Relaxation through a Peripheral Mode of Action , 2009, Journal of Pharmacology and Experimental Therapeutics.

[38]  J. Tack.  Prokinetics and fundic relaxants in upper functional GI disorders. , 2008, Current opinion in pharmacology.

[39]  P. Ducrotte,et al.  Clinical trial: radiofrequency energy delivery in proton pump inhibitor‐dependent gastro‐oesophageal reflux disease patients , 2008, Alimentary pharmacology & therapeutics.

[40]  A. Bredenoord,et al.  Esophageal pH-Impedance Monitoring in Patients With Therapy-Resistant Reflux Symptoms: ‘On’ or ‘Off’ Proton Pump Inhibitor? , 2008, The American Journal of Gastroenterology.

[41]  H. El‐Serag.  Role of obesity in GORD-related disorders , 2008, Gut.

[42]  I. Forgacs,et al.  Overprescribing proton pump inhibitors , 2008, BMJ : British Medical Journal.

[43]  A. Bredenoord,et al.  Mechanisms of acid, weakly acidic and gas reflux after anti-reflux surgery , 2007, Gut.

[44]  J. Dent,et al.  The Montreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus , 2006, The American Journal of Gastroenterology.

[45]  C. Camargo,et al.  Body-mass index and symptoms of gastroesophageal reflux in women. , 2006, The New England journal of medicine.

[46]  G. Jamieson,et al.  OPTIMIZATION OF OUTCOME AFTER LAPAROSCOPIC ANTIREFLUX SURGERY , 2006, ANZ journal of surgery.

[47]  S. Shay,et al.  Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring , 2006, Gut.

[48]  J. Tack,et al.  Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a double‐blind, placebo‐controlled study , 2006, Alimentary pharmacology & therapeutics.

[49]  M. Numans,et al.  Short-Term Treatment with Proton-Pump Inhibitors as a Test for Gastroesophageal Reflux Disease , 2004, Annals of Internal Medicine.

[50]  J. Tack,et al.  Effect of the GABAB agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors , 2003, Gut.

[51]  G. Triadafilopoulos.  Stretta: an effective, minimally invasive treatment for gastroesophageal reflux disease. , 2003, The American journal of medicine.

[52]  P. Kahrilas.  Radiofrequency therapy of the lower esophageal sphincter for treatment of GERD. , 2003, Gastrointestinal endoscopy.

[53]  L. Marzio,et al.  Effect of acute and chronic administration of the GABAB agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease , 2003, Gut.

[54]  D. Castell,et al.  Baclofen decreases acid and non‐acid post‐prandial gastro‐oesophageal reflux measured by combined multichannel intraluminal impedance and pH , 2003, Alimentary pharmacology & therapeutics.

[55]  J. Dent,et al.  Control of transient lower oesophageal sphincter relaxations and reflux by the GABAB agonist baclofen in patients with gastro-oesophageal reflux disease , 2002, Gut.

[56]  D. Castell,et al.  Imipramine decreases oesophageal pain perception in human male volunteers , 1998, Gut.

[57]  J. Peters,et al.  Multivariate analysis of factors predicting outcome after laparoscopic Nissen fundoplication , 1998, Journal of Gastrointestinal Surgery.

[58]  B. Hirschowitz,et al.  A critical analysis, with appropriate controls, of gastric acid and pepsin secretion in clinical esophagitis. , 1991, Gastroenterology.

[59]  S. Horgan,et al.  Esophageal sphincter device for gastroesophageal reflux disease. , 2013, The New England journal of medicine.

[60]  J. Dent,et al.  Radiofrequency energy delivery to the gastric cardia inhibits triggering of transient lower esophageal sphincter relaxation and gastroesophageal reflux in dogs. , 2003, Gastrointestinal endoscopy.

[61]  J. Dent,et al.  Control of transient lower esophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in normal subjects. , 2000, Gastroenterology.